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Background: Efavirenz (EFV) based antiretroviral therapy is expanding worldwide. However discontinuation of
EFV containing regimens is common in somepatients, particularly black patients, duemost often to neuropsychi-
atric side effects. These adverse drug effects often result in premature drug discontinuation, as well as consider-
able morbidity.
Methods:Wegenotyped CYP2A6, CYP2B6 and CYP3A4, which encode enzymes principally involved in EFVmetab-
olism, from patients enrolled in the multinational SMART, FIRST and ESPRIT studies, for whom outcome data of
treatment adherence was available. Patients with loss or decrease of function single nucleotide polymorphisms
(SNPs) in the above genes were assigned a risk score based upon the number of SNPs present weighted relative
to whether CYP2B6 (main metabolism pathway) and/or CYP2A6 and CYP3A4 (accessory pathways) were in-
volved. Cox regression models were used to study the association between high genetic risk and time from ini-
tiation to EFV discontinuation. Failure was deﬁned as discontinuation of an antiretroviral regimen other than for
virologic failure or protocol determined discontinuation.
Findings: Patients with highest pharmacogenetic risk, as deﬁned by cumulative SNPs in CYP2A6, CYP2B6 and
CYP3A4, have an increased risk of discontinuation of EFV containing therapy compared to patients with lower ge-
netic risk scores (adjusted HR 1.9, 95% CI 1.2, 3.1, P = 0.009). High genetic risk score was not associated with an
increased risk of discontinuing atazanavir or nevirapine. High genetic riskwas presentmore often in blacks com-
pared to non-blacks (Adjusted OR 4.5, 95% CI: 1.9,10.5), and treatment discontinuation was also increased in
blacks overall (Adjusted HR 1.4, 95% CI 1.0, 1.9). However, high genetic risk wasmore associated with treatment
discontinuation than race alone for both blacks (Adjusted OR 1.9, 95% CI 0.8, 4.8) and non-blacks (Adjusted OR
5.3, 95% CI 1.5, 18.0).
Interpretation: Premature discontinuation of ART delays the time to effective long term viral suppression, and is asso-
ciated with signiﬁcant morbidity. Pharmacogenetic testing may predict those with a high risk of EFV discontinuation,
and therefore should be considered in patients in whom initiation of EFV based ART is being considered.
Funding: Funded by NIH.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Effective combination antiretroviral therapy (cART)has dramatically
changed the clinical course of HIV infection. However, this clinicalr, MN 55905, United States.
mmins).
. This is an open access article undersuccess requires affordable access to medications, and lifelong adher-
ence. Speciﬁc antiretroviral agents may have high rates of adverse
drug effects (ADEs), which lead to discontinuation of otherwise effec-
tive (i.e., virologically suppressive) treatment regimens in up to 40% of
patients within 1 year (Durability of ﬁrst ART regimen and risk factors
for modiﬁcation, interruption or death in HIV-positive patients starting
ART in Europe andNorth America, 2002–2009, 2013). TheWorld Healththe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Genetic risk score for premature discontinue of efavirenz.
Score 1 (reference score): Homozygous for the reference allele in all 3 genes
Score 2: Homozygous for the reference allele for CYP2B6, and 1 to 4 LOF/DOF alleles
for CYP2A6 and CYP3A4
Score 3: 1 LOF/DOF allele for CYP2B6 but no LOF/DOF allele for CYP2A6 and CYP3A4
Score 4: 1 LOF/DOF allele for CYP2B6 and 1 to 4 LOF/DOF alleles for CYP2A6 and
CYP3A4
Score 5: 2 LOF/DOF alleles for CYP2B6 but no LOF/DOF allele for CYP2A6 and CYP3A4
Score 6: 2 LOF/DOF alleles for CYP2B6 and 1 to 4 LOF/DOF alleles for CYP2A6 and
CYP3A4
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Health and Human Services (Adolescents PoAGfAa, 2014; Gunthard
et al., 2014) recommend efavirenz (EFV) containing regimens as ini-
tial ﬁrst line therapy for HIV, due to once daily dosing which pro-
motes compliance, and favorable long term treatment outcomes. In
addition EFV came off patent in November 2013, making generic ver-
sions of this drug more affordable particularly in resource poor set-
tings (Walensky et al., 2013). However, treatment discontinuation
occurs in up to 20% percent of patients on once daily EFV based ther-
apy (Scourﬁeld et al., 2012; Walmsley et al., 2013), due primarily to
the ADE's associated with EFV: central neuro-psychiatric symptoms,
dizziness, lightheadedness, confusion and abnormal dreams, and a
higher likelihood of committing suicide than patients on other
agents (Katie Mollan et al., 2013; Mollan et al., 2014). The WHO esti-
mates that 16.8 million persons living with HIV in low- and middle-
income countries will be using cART by 2016, and it is estimated that
the global market share of EFV among non-nucleotide reverse tran-
scriptase inhibitor based regimens will increase from 40% to 63%
(Organization WH, 2014). Given the effectiveness of EFV, and its in-
creasing affordability, it is of global public health importance to accu-
rately predict those patients who will tolerate EFV, particularly in
light of the expanding use of EFV in resource limited settings
(Takuva et al., 2013).SMART VS Group with DNA 
available and 
- On ART and no history of EFV or  
ATV or
- ART naïve
N=830
N=241
Did not start 
EFV or NVP 
or switch to 
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follow-up on 
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N=485
N=431
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N = 963
N=186
Insufficient 
DNA sample 
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N=758 total inclu
Fig. 1. Participant eligibility and exclusion stratEFV undergoes hepatic metabolism catalyzed by cytochromes P450
CYP2B6 (main pathway), and CYP2A6 and CYP3A4 (accessory path-
ways) (Desta et al., 2007; Telenti and Zanger, 2008). Single nucleotide
polymorphisms (SNPs) in CYP2B6, CYP2A6 and CYP3A4 exist that result
in loss of function (LOF) or decrease of function (DOF), which associate
with slower EFVmetabolism and consequently increased drug levels (di
Iulio et al., 2009; Arab-Alameddine et al., 2009). Because the risk of EFV
associated neuro-psychiatric symptoms is increased in patients with
higher plasma concentrations (Marzolini et al., 2001) (Csajka et al.,
2003) (Gounden et al., 2010) (Nanzigu et al., 2012; Gutierrez et al.,
2005), it is likely that patients who have SNPs in CYP2B6, CYP2A6 and
CYP3A4, will have a higher incidence of EFV intolerance. Indeed, in 831
participants from three AIDS Clinical Trials group studies, SNPs in
CYP2B6were associated with an increased likelihood of a CNS adverse
effect from EFV (Ribaudo et al., 2010), and in a separate study of 577 pa-
tients, SNPs in all three enzymes, CYP2A6, CYP2B6 and CYP3A4, were as-
sociated with discontinuation of EFV-based regimenswithin 12months
of initiation (Lubomirov et al., 2011).
In the studies referenced above, the majority of subjects were non-
black (66% in (Ribaudo et al., 2010) and 80% in (Lubomirov et al.,
2011)), yet the greatest increase in EFV use is likely in populations
that are of broader ethnicity, thus it is of importance to determine
whether SNP analysis is associated with EFV discontinuation in mixed
ethnicity populations. We therefore sought to determine if pharmaco-
genetic testing of select SNPs in CYP2B6, CYP2A6, and CYP3A4would be
associated with premature treatment discontinuation of virologically
suppressive, EFV-containing ART regimens in a multi-national, mixed
ethnicity cohort of patients with a long duration of follow up.
2. Materials and Methods
2.1. Participants
Participants included in this study were HIV-positive patients who
participated in studies conducted by INSIGHT (International Network<12 mo. 
follow-up on 
EFV or ATV 
N=5
Insufficient 
DNA sample
N=54
Did not 
switch to 
EFV or ATV
N=473
Did not start or 
switch to EFV 
or NVP
N=107
up with 
V
FIRST with DNA available
N = 545
N=438
N=265
N=220
<12 mo. 
follow-up on 
EFV or NVP 
N=173
Insufficient 
DNA sample
N=45
ded in analysis
iﬁed by study (SMART, ESPRIT and FIRST).
Fig. 2. Number of study participants with each EFV genetic score (from 1 [lowest] to 6
[highest]) is depicted according to race (Asian, black, white or others).
708 N.W. Cummins et al. / EBioMedicine 2 (2015) 706–712for Strategic Initiatives in Global HIV Trials) and the Community Pro-
grams for Clinical Research on AIDS (CPCRA). The INSIGHT SMART
(Strategies for Management of Anti-Retroviral Therapy) study opened
in January 2002 and enrolled 5472 participants. Patients could be
cART-naïve or experienced (El-Sadr et al., 2008). The INSIGHT ESPRIT
(Evaluation of Subcutaneous Proleukin® in a Randomized International
Trial) study opened in March 2000 and enrolled 4150 patients. ESPRIT
enrolled patients who were taking cART at study entry (Abrams et al.,
2009). The CPCRA FIRST (Flexible Initial Retrovirus Suppressive Thera-
pies) study enrolled 1397 patients who were ART-naïve from 1999 to
2002 (MacArthur et al., 2006). For the SMART and FIRST studies, ART-
naïve patients beginning their ﬁrst EFV-based or nevirapine (NVP)-
based regimen at study entrywere included. For SMART and ESPRIT, pa-
tients who were cART experienced and who switched to EFV or
atazanavir (ATV) during follow-up were included. For the FIRST study,
control participants on only 2 classes of drugs were included.
Inclusion criteria for this investigation included 1) signed informed
consent for collection and preservation of DNA samples, 2) DNA sam-
ples available for testing, and 3) presence of a minimum of 12 months
of followupdata concerning antiretroviral therapy adherence, duration,
changes, side effects and ADEs. Patients were excluded if virologic fail-
ure led to treatment discontinuation or change. Written informed con-
sent was obtained for participation in each trial and for the collection
of blood for DNA extraction for the future studies of genetic variants.
Participants were enrolled in 26 countries from 6 different conti-
nents. Over half (57%) were enrolled in North America, 21% were en-
rolled in Europe, 9% in South America, 8% in Asia, 4% in Australia and
1% in Africa.2.2. Genotyping
Among patients who consented, DNA was extracted and 6 loss
of function (LOF) or decrease of function (DOF) SNPs, in CYP2A6
(rs28399433 [risk allele C]), CYP2B6 (rs28399499 [G], rs35303484 [G],Table 2a
Baseline characteristics of participants by genetic risk score (INSIGHT).
Characteristic Scores 1–5
No. 718
Age in years (median, IQR; OR per 10 year increase) 40 (34, 45)
Female (%) 21.3
Black race (%) 22.1
CD4 T cell count in cells/mm3 (median, IQR; OR per 100 cell increase) 414 (280, 571)
HIV RNA (% b 500 copies/) 44.3
BMI kg/m2 (median, IQR; OR per 5 kg/m2 increase) 24.0 (21.8, 26.4
Hepatitis B or C co-infection (%) 13.1
a Unadjusted, stratiﬁed by study.
b Adjusted for age, gender, race, CD4 T cell count, HIV RNA, BMI, and hepatitis co-infection ars35979566 [A], rs3745274 [A]), and CYP3A4 (rs4646437 [A]) were
assessed using the Illumina VeraCode™ Genotyping Assay. The
BeadArrays were scanned in an Illumina BeadXpress™ reader and the
ﬂuorescent signals analyzed with Illumina GenomeStudio software,
with automated genotype clustering and calling. A genetic risk score
from 1 (lowest risk) to 6 (highest risk) based on the presence of LOF
and DOF SNPs was deﬁned a priori (Lubomirov et al., 2011) and calcu-
lated for each participant (Table 1).2.3. Statistical Analysis
Descriptive statistics were used to describe baseline characteristics
of study participants. For ART-naïve patients, characteristics at study
entry are given; for those that were cART-experienced, characteristics
at the time the EFV or ATV regimen was initiated during follow-up are
given. Logistic regression models were used to study factors measured
at treatment initiation associated with genetic risk score. Unadjusted
and adjusted odds ratios (OR) (genetic score of 6 versus 1–5) are
given with 95% conﬁdence intervals (CIs).
Time to event methods (Kaplan–Meier survival scores and Cox re-
gression) were used to compare time from initiation to discontinuing
EFV according to genetic risk score. Discontinuation of a single drug
for any reason was considered because detailed information regarding
reasons for discontinuation was not collected. In the Cox regression
models, the following baseline covariates were considered: age, gender,
race, CD4+T cell count, HIV-RNA, BMI and co-infectionwith hepatitis B
or C to estimate adjusted hazard ratios (HRs) of discontinuing EFV (ge-
netic risk score of 6 versus 1–5) (Lubomirov et al., 2011). These models
were stratiﬁed by study (SMART, ESPRIT, and FIRST). Separate and com-
binedmodels for ART-naïve andART-experiencedpatientswere consid-
ered. To increase conﬁdence that the associations found were due to
EFV, as negative controls, we also estimated the risk of discontinuingne-
virapine (NVP) and atazanavir (ATV) associated with the genetic
risk score. A priori, no association of the genetic risk score with
discontinuing these treatments was expected. For these analyses, ex-
panded Coxmodels with interaction termswere used to assesswhether
the risk of discontinuation of EFV associated with the genetic risk score
differed from that of NVP and ATV.
We also carried out pooled analyses using individual level data pre-
viously published from the Swiss Cohort Study (Lubomirov et al., 2011).
For this analysis, a 12 month follow-up period was considered in both
studies. Logistic regression was used to study the association of genetic
risk score with EFV discontinuation by 12 months. Odds ratios (ORs)
and 95% CIs are cited for scores of 1 through 5, each versus a score of
6. The logistic model was stratiﬁed by study and included covariates
corresponding to age, gender, race, CD4+ T cell count, HIV RNA level,
BMI and hepatitis co-infection. The pooled analyses were also carried
out for self-identiﬁed blacks and non-blacks separately.
Two-sided p-values less than 0.05was considered statistically signif-
icant. Statistical analyses were performed using SAS software (version
9.3).Score 6 OR (95% CI) score 6 vs 1–5a OR (95% CI) score 6 vs 1–5b
40
37 (34, 41) 0.8 (0.5, 1.1) 0.8 (0.5, 1.1)
47.5 3.3 (1.7, 6.4) 2.1 (1.0, 4.3)
65.0 5.5 (2.6, 12.0) 4.5 (1.9, 10.5)
312 (136, 520) 0.9 (0.8, 1.1) 1.0 (0.8, 1.1)
22.5 0.6 (0.2, 1.4) 0.7 (0.3, 1.9)
) 23.9 (22.0, 27.7) 1.1 (0.8, 1.6) 1.0 (0.7, 1.3)
10.0 1.1 (0.4, 3.4) 1.1 (0.4, 3.6)
nd stratiﬁed by study.
Table 2b
Baseline characteristics of participants by genetic risk score (Swiss Cohort).
Characteristic Scores 1–5 Score 6 OR (95% CI) score 6 vs 1–5a OR (95% CI) score 6 vs 1–5b
No. 259 13
Age in years (median, IQR; OR per 10 year increase) 39 (34, 47) 36 (32, 42) 0.7 (0.4, 1.3) 1.2 (0.6, 2.5)
Female (%) 25.5 61.5 4.7 (1.5, 14.8) 1.8 (0.5, 6.8)
Black race (%) 14.7 76.9 19.4 (5.1, 73.7) 17.5 (3.6, 84.4)
CD4 T cell count in cells/mm3 (median, IQR; OR per 100 cell increase) 207 (119, 269) 204 (152, 248) 0.9 (0.6, 1.4) 0.9 (0.4, 1.7)
HIV RNA (log10 copies/ml) 4.9 (4.4, 5.4) 4.6 (4.4, 4.9) 0.8 (0.4, 1.5) 0.8 (0.3, 2.0)
BMI kg/m2 (median, IQR; OR per 5 kg/m2 increase) 22.6 (20.9, 24.6) 23.0 (21.4, 25.3) 1.0 (0.5, 2.2) 0.9 (0.4, 2.3)
Hepatitis B or C co-infection (%) 45.6 53.8 1.4 (0.5, 4.3) 0.9 (0.3, 3.1)
a Unadjusted.
b Adjusted for age, gender, race, CD4 T cell count, HIV RNA, BMI, and hepatitis co-infection.
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1134 participants were identiﬁed as meeting inclusion criteria,
whereas 1204 participants did not. Of these, 761 (67%) participants
had DNA of sufﬁcient quantity and quality to perform the genotyping
assay. After genotyping, 3 participants were excluded due to uninter-
pretable assay results. Thus, the analyses in this report are based on a
total of 758 patients (See Fig. 1 for ﬂow diagram).
Of the 758 patients, 131 (17%) were ART naïve and initiated EFV as
their ﬁrst regimen and 315 (42%) were ART experienced who switched
to EFV from another regimen. Eighty (11%) participants were ART naïve
and initiated nevirapine (NVP) and 232 (31%) participantswere ART ex-
periencedwho switched to atazanavir (ATV) fromanother regimen. The
characteristics of these patients at the time their cART regimen was ini-
tiated are summarized in Supplemental Tables 1 and 2. Of interest, 24%
of all patientswere black, which is a population known to have a greater
incidence of premature cART discontinuation (Ribaudo et al., 2013).3.1. Pre-treatment Factors Associated With High Genetic Risk Score
Genetic risk score was calculated based on accumulation of LOF and
DOF SNPs in CYP2A6, CYP2B6 and CYP3A4 as previously described (see
Table 1 and (Lubomirov et al., 2011)). Overall, 40 patients (5.3%) had
a genetic risk score of 6 (Fig. 2), 26 of whomwere black. The prevalence
of a high genetic risk in blacks was 26/185 (14.1%), whereas for non-
blacks it was 14/573 (2.4%) (unadjusted OR (black/non-black) for a ge-
netic risk score of 6 was 5.5; 95% CI:2.6–12.0; p b 0.001 Tables 2a and
2b). Therefore while EFV toxicity occurs commonly in blacks, the prev-
alence of high genetic risk remains uncommon in blacks, and even less
common in non-blacks. Apart from the black race, and gender (female
vs male unadjusted OR 3.3 (1.7–6.4), p b 0.001; adjusted OR 2.1 (1.0,
4.3), p = 0.04) there were not signiﬁcant associations with the genetic
risk score.Table 3
Risk of premature treatment discontinuation of effective antiretroviral therapy according to ge
Patient group N (ratea) with
scores 1–5
who discontinued
N (ratea) with
score 6
who discontinued
Un
dis
sco
ART naïve who started EFV
(N = 131)
85 (25.1) 7 (69.4) 2.5
ART experienced who switched
to EFV (N = 315)
174 (21.4) 13 (38.9) 1.7
All who started EFV (N = 446) 259 (22.5) 20 (45.9) 2.0
ART naïve who started
NVP (N = 80)
56 (34.9) 9 (37.7) 1.2
ART experienced who switched to
ATV (N = 232)
91 (16.6) 1 (9.6) 0.6
a Per 100 person-years.
b Adjusted for age, gender, race, CD4 T cell count, HIV RNA, BMI, and hepatitis co-infection a3.2. Association of Genetic Risk Score With Treatment Discontinuation
Participants with genetic risk scores of 1–5 had similar rates of dis-
continuation (range; 14 to 26 per 100 person years, p = 0.10 for differ-
ence), thus those groups were combined. Participants with a genetic
risk score of 6 had a signiﬁcantly increased risk of discontinuing effec-
tive ART regimens containing EFV compared to participants with risk
scores of 1–5 (HR 2.0 (95% CI 1.2, 3.1); P = 0.004). Conversely patients
with a high genetic riskwere notmore likely to discontinue ATV or NVP
(HR 0.6 (95% CI 0.1, 4.5) P= 0.64 and HR 1.2 (0.6, 2.6) P= 0.54 respec-
tively). This effect was apparent in both ART naïve participants who ini-
tiated EFV based regiments (HR 2.5 (95% CI 1.2, 5.4); P = 0.02) and in
ART experienced patients who switched to EFV based regimens (HR
1.7 (95% CI 0.9, 3.0); P = 0.08). The increased risk for EFV discontinua-
tion in participants with risk score of 6 persisted after adjustment for
age, gender, race, CD4 T cell count, HIV RNA, bodymass index, hepatitis
co-infection and stratiﬁed by study (HR 1.9 (95% CI 1.2, 3.1); P= 0.009,
Table 3). Importantly, black subjects were only slightly more likely to
discontinue EFV than non-blacks, (HR 1.4, 95% CI 1.0, 1.9) indicating
that genetic risk scorewas superior to race in associatingwithwhichpa-
tients discontinued EFV. EFV discontinuation occurred as early as two
months after starting EFV containing therapy and continued to occur
up until to 60 months of follow up (Fig. 3).3.3. Pooled Analysis With Swiss Cohort
A pooled analysis of the CPCRA and INSIGHT studies together with
the Swiss Cohort (Gutierrez et al., 2005) was carried out to increase
the power to determine if there was a graded relationship of the score
with risk of discontinuation of EFV (Table 4). Each of the lower scores,
1–5, was associated with a reduced risk of EVF discontinuation com-
pared to a score of 6. However, the risk associated with scores 1–5 did
not vary (p = 0.15).netic risk score.
adjusted HR (95% CI) for
continuation of ART,
re 6 vs 1–5
P value Adjustedb HR (95% CI) for
discontinuation of ART, score
6 vs 1–5
P value
(1.2, 5.4) 0.02 2.2 (1.0, 4.9) 0.05
(0.9, 3.0) 0.08 1.6 (0.9, 3.0) 0.13
(1.2, 3.1) 0.004 1.9 (1.2, 3.1) 0.009
(0.6, 2.6) 0.54 1.5 (0.6, 3.7) 0.35
(0.1, 4.5) 0.64 0.6 (0.1, 4.8) 0.65
nd stratiﬁed by study.
Fig. 3. Kaplan–Meier estimates of the cumulative percentage patients on EFV-containing
regimens who discontinued the regimen comparing high genetic risk patients (Score
6) to average genetic risk patients (Scores 1 to 5).
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Because high genetic risk score was over-represented in black par-
ticipants, we conducted population stratiﬁcation analyses based on
race and study (Tables 5a and 5b). The risk of discontinuation of EFV
was increased for thosewith high genetic risk score for both blacks (Ad-
justed OR 1.9 (p = 0.18)) and non-blacks (Adjusted OR 5.3 (p =
0.008)), indicating that pharmacogenetic prediction was associated
with increased risk of EFV discontinuation independent of self-
identiﬁed race.
4. Discussion
EFV-based regimens are recommended as ﬁrst-line and command a
substantialmarket share of current ART use; yet as EFV is nowoff patent
and generic versions are available at lower cost, it is likely that the use of
EFV containing regimens will increase in resource limited settings
where cost of medications has prohibitedwidespread access to therapy.
However EFV discontinuation rates for non-virologic reasons (i.e., for
reasons other than viral resistance) can reach as high as 20% and there-
fore being able to a priori discriminate those who are more likely to tol-
erate EFV based therapy is of great global health importance. Herein
we demonstrate in a multiethnic population, individuals with loss or
decrease of function alleles for 2 ormore EFVmetabolizing enzymes, in-
cluding CYP2B6, are at ~2-fold increased risk of premature discontinua-
tion of EFV, irrespective of race or any other factor.
As EFV becomes a more affordable and widespread option for HIV
care, a pharmacogenetic test that accurately discriminates those pa-
tients who will discontinue EFV for ADE reasons could be an important
addition to the clinician's decision tools for selecting cART regimens for
individual patients. HLA-B*5701 testing to predict abacavir hypersensi-
tivity signiﬁcantly inﬂuenced the care of HIV, by allowing the safe useTable 4
Risk of premature treatment discontinuation of effective antiretroviral therapy according to ge
Genetic
risk score
N (%) who discontinued
within ﬁrst year: INSIGHT
N (%) who discontinued within
ﬁrst year: Swiss Cohort
Unad
disco
vs. s
Score 1 31 (28.4) 22 (30.6) 0.38
Score 2 30 (28.6) 16 (28.6) 0.38
Score 3 16 (18.4) 14 (21.9) 0.23
Score 4 29 (27.6) 19 (35.2) 0.41
Score 5 2 (12.5) 3 (23.1) 0.19
Score 6 12 (50.0) 7 (53.8) 1.0
Total 120 (26.9) 81 (29.8)
a Stratiﬁed by study.
b Adjusted for age, gender, race, CD4 T cell count, HIV RNA, BMI, and hepatitis co-infection aof amedication that had life threatening ADE potential. Notably, the fre-
quency of the highest genetic risk score in the present study (5.3%) is
similar to the reported frequency of HLA-B*5701 (Orkin et al., 2010).
Being able to determine who will tolerate EFV may enhance the ability
of patients who take EFV to tolerate EFV, lower risk of developing
NNRTI resistance due to missed doses, and reduced morbidity due to
ADEs. Each of these predictions is testable and warrants further study.
This may lead to cost savings through less work and school absences,
less need to switch cART regimens and incur the additional expense
and inconvenience of doctor visits and lab tests needed to initiate and
monitor a therapy change. This may not necessarily be the case though;
the rate per 100 person years for stopping EFV (including ART experi-
enced and naïve combined) in our study was 23.3. The corresponding
rate for stopping NVP was 35.3; however, better tolerated agents are
available now, including integrase inhibitors, which could be used in-
stead of EFV or NVP. An alternative strategy could be reducing EFV
dose. Evidence supporting reduced dosing for EFV is found in the EN-
CORE1 trial where reduced dose EFV (400 mg) was non-inferior to
600 mg EFV for virologic suppression, and study-drug related ADEs
(Puls et al., 2014); it would be of great interest to stratify such an anal-
ysis by genetic risk score.
In our study, those participants with the highest genetic risk score of
6 had an increased risk for EFV discontinuation compared to those par-
ticipants with risk scores 1–5. We therefore performed a post hoc anal-
ysis of pooled data of 781 patients starting EFV-based regimens from
our cohort and the patients in the Swiss Cohort (Lubomirov et al.,
2011) and that showed the risk of EFV discontinuation did not change
in patients with genetic risk scores of 1–5, likely reﬂecting the known
redundancy in EFV metabolizing pathways, and is consistent with data
in patients with CYP2B6 polymorphisms 516G N T and 983 T N C
where plasma EFV plasma concentrations were elevated only in those
patients who also had other accessory pathway mutations (Haas et al.,
2014).
Black participants in our cohort had a higher prevalence (14.1%) of
high genetic risk compared to other races (2.4%), consistent with re-
ported population allele frequencies for variants in those genes
(http://www.ncbi.nlm.nih.gov/snp/). A high prevalence of CYP2B6
516G N T (rs3745274) has been previously reported in Ghanaian pa-
tients (Sarfo et al., 2014), and racial differences in the prevalence are ev-
ident in HapMap and 1000 Genomes data (35–42% in Sub-Saharan
Africans, 23–27% in Europeans, 15–18% in Asians). Thus if an individual
with this allele also happens to have other LOF/DOF alleles in EFV me-
tabolizing enzymes, it is logical that they might be intolerant to EFV. It
is noteworthy however that race alone did not predict EFV discontinua-
tion in our analyses — indicating that the pharmacogenetic risk
stratiﬁcation employed in our study is more discriminatory than deter-
mination of race alone. In addition, it is likely that factors other than ge-
netic risk contribute to disparities in treatment discontinuation which
could contribute to an attenuation of observed genetic risk.
There are potential limitations of our study. Our study focused on
three CYP enzymes, and thus on pharmacokinetic pharmacogenetics.
There might be other pharmacokinetic factors, e.g., geneticallynetic risk score— pooled analysis with Swiss Cohort.
justeda OR (95% CI) for
ntinuation in ﬁrst year,
core of 6
P value Adjustedb OR (95% CI) for
discontinuation in ﬁrst year,
vs. score of 6
P value
(0.19, 0.79) 0.009 0.41 (0.18, 0.90) 0.03
(0.18, 0.79) 0.01 0.36 (0.17, 0.77) 0.009
(0.11, 0.49) b0.001 0.24 (0.10, 0.54) b0.001
(0.20, 0.85) 0.02 0.39 (0.18, 0.82) 0.01
(0.06, 0.60) 0.005 0.20 (0.06, 0.65) 0.008
– 1.0 –
nd stratiﬁed by study.
Table 5a
Risk of premature treatment discontinuation of effective antiretroviral therapy according to genetic risk score – Pooled analysis with Swiss Cohort – Black race (N= 166).
Genetic Risk
Score
N (%) who discontinued
within ﬁrst year: INSIGHT
N (%) who discontinued within
ﬁrst year: Swiss Cohort
Unadjusteda OR (95% CI) for
discontinuation in ﬁrst year,
vs. score of 6
P value Adjustedb OR (95% CI) for
discontinuation in ﬁrst
year, vs. score of 6
P value
Score 1 2 (28.6) 1 (100.0) 0.96 (0.18, 5.04) 0.96 0.60 (0.08, 4.47) 0.62
Score 2 11 (29.7) 1 (9.1) 0.44 (0.16, 1.24) 0.12 0.37 (0.12, 1.14) 0.08
Score 3 2 (50.0) 0 (0) 1.44 (1.17, 12.4) 0.74 2.46 (0.24, 25.1) 0.45
Score 4 14 (25.9) 10 (41.7) 0.58 (0.23, 1.47) 0.25 0.54 (0.20, 1.46) 0.23
Score 5 1 (100.0) 1 (50.0) 1.97 (0.16, 24.7) 0.60 2.87 (0.17, 48.1) 0.46
Score 6 7 (46.7) 7 (40.0) 1.0 – 1.0 –
Total 37 (31.4) 17 (35.4)
Score 6 vs. scores 1–5 1.71 (0.72, 4.08) 0.23 1.89 (0.75, 4.78) 0.18
a Stratiﬁed by study.
b Adjusted for age, gender, CD4 T cell count, HIV RNA, BMI, and hepatitis co-infection and stratiﬁed by study.
711N.W. Cummins et al. / EBioMedicine 2 (2015) 706–712polymorphic transporters, that contribute to premature discontinu-
ation of EFV that were not assessed here. It is also conceivable that
some of the side effects might also be inﬂuenced by pharmacody-
namic pharmacogenetics — i.e., genetic variation in the targets for
the drug. In addition, since we included only those participants
with 12 months of follow up data, there is the potential for survivor-
ship bias. Finally, data was not available in all studies regarding preg-
nancy as a potential cause for premature treatment discontinuation.
Future studies should take these potential factors into account.
In conclusion, given the signiﬁcant association of high genetic risk
score with EFV but not NVP or ATZ discontinuation in a multiethnic co-
hort, assessment of this score is warranted in large prospective interna-
tional cohorts. The cost effectiveness of this strategy would need to be
determined, particularly in resource-limited settings.
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